Cipla Ltd USFDA observations at Pharmathen

The USFDA flagged multiple compliance lapses at Pharmathen International's facility (a Cipla partner for complex generics), leading to a sharp 4–5% drop in Cipla shares to around ₹1,465–₹1,455 intraday on January 6–7, 2026. The observations include manufacturing and quality control issues; Cipla has not yet commented, but this could delay approvals or supplies for partnered products, adding short‑term regulatory overhang.